Isoniazid-rifampin-induced hepatitis in hepatitis B carriers.
case_control · Level III
Where this comes from
- Record sourced from PubMed, PMID 2295408.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
From January 1984-December 1987, 1783 patients received combination therapy of isoniazid, rifampin, and ethambutol for the control of tuberculosis. Forty-two developed symptomatic hepatitis during the period of treatment. Fifteen were hepatitis B virus carriers, and the remaining 27 were noncarriers. The peak serum transaminase and bilirubin levels were higher in carriers. Seven carriers died of fulminant or subacute hepatic failure, and only 1 noncarrier died. Eleven carriers had detectable serum hepatitis B virus deoxyribonucleic acid during the acute stage of hepatitis. The roles of isoniazid-rifampin combination therapy and hepatitis B virus in the adverse outcomes of carriers were discussed.
Medical subject headings
- Carrier State
- Chemical and Drug Induced Liver Injury
- Hepatitis B
- Isoniazid
- Rifampin
- Tuberculosis, Pulmonary